SBRT for Adenoid Cystic Carcinoma
What You Need to Know Before You Apply
What is the purpose of this trial?
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival.The name(s) of the study intervention involved in this study is:* Stereotactic Body Radiation Therapy (SBRT)
Will I have to stop taking my current medications?
You will need to stop any systemic therapy (like certain cancer drugs) at least 2 weeks before starting the radiation treatment and until after the last session of SBRT. Other medications are not specifically mentioned, so it's best to discuss with the trial team.
Is stereotactic body radiation therapy (SBRT) generally safe for humans?
Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is generally considered safe for treating various tumors, but some serious complications have been reported. The risk of side effects can vary depending on the location of the tumor, with higher risks near sensitive structures like the bronchial tree. Strategies are in place to reduce these risks and improve safety.12345
How is SBRT treatment different for adenoid cystic carcinoma?
SBRT (Stereotactic Body Radiation Therapy) is unique because it delivers high doses of radiation precisely to the tumor while sparing surrounding healthy tissue, which is particularly beneficial for treating lung metastases from adenoid cystic carcinoma that are resistant to conventional radiotherapy.678910
What data supports the effectiveness of the treatment SBRT for Adenoid Cystic Carcinoma?
Stereotactic Body Radiation Therapy (SBRT) has shown effectiveness in treating various cancers, such as non-small cell lung cancer, by delivering precise, high doses of radiation to tumors while minimizing damage to surrounding healthy tissue. This approach has been associated with high local control rates and low toxicity, suggesting potential benefits for treating other types of tumors, including Adenoid Cystic Carcinoma.111121314
Who Is on the Research Team?
Jonathan D. Schoenfeld, MD MPH
Principal Investigator
Brigham and Women's Hospital
Are You a Good Fit for This Trial?
This trial is for adults with adenoid cystic carcinoma that has spread to other parts of the body. Participants should have 1-5 metastatic sites, a stable primary tumor, and an ECOG performance status of 0-2. Women must not be pregnant and agree to contraception measures. No recent systemic therapy (4 weeks before radiotherapy) is allowed.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive stereotactic body radiotherapy (SBRT) to 1-5 sites of metastatic disease over the course of 1-8 business days
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments for progression-free survival and overall survival
Optional Systemic Therapy
Participants may receive systemic therapy such as chemotherapy, immunotherapy, or targeted therapies at the discretion of their treating physician after SBRT
What Are the Treatments Tested in This Trial?
Interventions
- SBRT
SBRT is already approved in United States, European Union, Canada, Japan for the following indications:
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Spinal tumors
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Spinal tumors
- Bone metastases
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Spinal tumors
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Adenoid Cystic Carcinoma Research Foundation
Collaborator
Gateway for Cancer Research
Collaborator
Adenoid Cystic Carcinoma Research Foundation
Collaborator